HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer
Authors
Keywords
-
Journal
Molecular Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-18
DOI
10.1002/1878-0261.12883
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors
- (2020) Kwon-Ho Song et al. Nature Communications
- Platinum Resistance in Ovarian Cancer: Role of DNA Repair
- (2019) Giovanna Damia et al. Cancers
- Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis
- (2019) Matthew Ho Zhi Guang et al. Cancers
- Epithelial ovarian cancer
- (2019) Stephanie Lheureux et al. LANCET
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Depletion of the RNA binding protein HNRNPD impairs homologous recombination by inhibiting DNA-end resection and inducing R-loop accumulation
- (2019) Luigi Alfano et al. NUCLEIC ACIDS RESEARCH
- Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake
- (2019) Geny Piro et al. MOLECULAR CANCER THERAPEUTICS
- A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition
- (2019) Kevin Shee et al. CLINICAL CANCER RESEARCH
- Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities
- (2019) Abdullah Hoter et al. Cancers
- Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
- (2019) Isabelle Ray-Coquard et al. Frontiers in Oncology
- Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells
- (2019) Ilaria Lorenzon et al. Cells
- TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells
- (2019) Maura Sonego et al. Cells
- Combined BRAF and HSP90 inhibition in patients with unresectableBRAFV600E mutant melanoma
- (2018) Zeynep Eroglu et al. CLINICAL CANCER RESEARCH
- Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
- (2018) Nicole Concin et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of the Hsp90 inhibitor Luminespib Among Non-Small Cell Lung Cancers Harboring EGFR Exon 20 Insertions
- (2018) Z Piotrowska et al. ANNALS OF ONCOLOGY
- Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small-cell lung cancer cells
- (2018) Maria Rita Milone et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The HSP90 chaperone machinery
- (2017) Florian H. Schopf et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Epidemiology of ovarian cancer: a review
- (2017) Reid Brett M. et al. Cancer Biology & Medicine
- Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
- (2017) Maura Sonego et al. Scientific Reports
- Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
- (2016) Daniela Kramer et al. CELL DEATH AND DIFFERENTIATION
- Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression
- (2016) M Zou et al. ONCOGENE
- Regulation and function of the human HSP90AA1 gene
- (2015) Abbey D. Zuehlke et al. GENE
- Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
- (2015) Anuj Khandelwal et al. MEDICINAL RESEARCH REVIEWS
- Loss of lamin A but not lamin C expression in epithelial ovarian cancer cells is associated with metastasis and poor prognosis
- (2015) Guanghui Gong et al. PATHOLOGY RESEARCH AND PRACTICE
- Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression
- (2015) Manuela Terranova-Barberio et al. Oncotarget
- Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype
- (2015) Milone Maria Rita et al. Oncotarget
- Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise
- (2014) D. A. Proia et al. CANCER RESEARCH
- Systems biology of cisplatin resistance: past, present and future
- (2014) L Galluzzi et al. Cell Death & Disease
- Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes
- (2013) P-N Teng et al. BRITISH JOURNAL OF CANCER
- Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer
- (2013) H. Liu et al. CLINICAL CANCER RESEARCH
- Genome engineering using the CRISPR-Cas9 system
- (2013) F Ann Ran et al. Nature Protocols
- HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer
- (2013) C-H Lai et al. ONCOGENE
- Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
- (2013) F Bruzzese et al. Cell Death & Disease
- Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer
- (2012) T. Shimamura et al. CLINICAL CANCER RESEARCH
- Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
- (2012) SUQIN HE et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells
- (2012) Shu-hua Chu et al. MOLECULAR BIOLOGY REPORTS
- Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
- (2011) W. Ying et al. MOLECULAR CANCER THERAPEUTICS
- The regulatory mechanism of Hsp90α secretion and its function in tumor malignancy
- (2009) Xiaofeng Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now